What are the recommended first‑line pharmacologic agents for primary hypertension in adults and how should treatment be escalated if blood pressure remains uncontrolled?

First-Line Pharmacologic Treatment for Primary Hypertension in Adults

For adults with confirmed hypertension, initiate treatment with upfront low-dose combination therapy using two drugs from the following four major classes: ACE inhibitors, ARBs, dihydropyridine calcium channel blockers (CCBs), or thiazide/thiazide-like diuretics, preferably as a single-pill combination. 1

Initial Drug Selection

Preferred First-Line Agents

The four major drug classes recommended for initial therapy are 1:

• ACE inhibitors (e.g., enalapril, lisinopril)
• Angiotensin receptor blockers (ARBs) (e.g., candesartan, losartan)
• Dihydropyridine calcium channel blockers (e.g., amlodipine)
• Thiazide or thiazide-like diuretics (e.g., chlorthalidone, hydrochlorothiazide)

Monotherapy vs. Combination Therapy

Stage 2 hypertension (BP >20/10 mmHg above target): Start with two first-line agents of different classes, either as separate agents or in a fixed-dose combination 2

Stage 1 hypertension: Single antihypertensive drug is reasonable with dosage titration and sequential addition of other agents to achieve BP target 2

Elevated BP with treatment indication: Monotherapy is recommended initially 1

Why Combination Therapy is Preferred

The 2024 ESC guidelines provide a Class I recommendation for upfront combination therapy because 1:

• Combining drugs from different classes produces additive or synergistic BP reduction
• Targets multiple pathophysiological pathways
• Allows lower doses of each agent, potentially reducing side effects
• Achieves swifter BP control, improving long-term adherence
• Single-pill combinations enhance adherence over separate pills

Critical caveat: Never combine two RAS blockers (ACE inhibitor + ARB) together 1

Drug Class Efficacy Differences

Thiazide diuretics (particularly chlorthalidone) demonstrate superior outcomes 2, 3:

• Low-dose thiazides reduce mortality (RR 0.89), total cardiovascular events (RR 0.70), stroke (RR 0.68), and coronary heart disease (RR 0.72) 3
• Chlorthalidone was superior to amlodipine and lisinopril in preventing heart failure 2

Beta-blockers are less effective and not recommended as first-line therapy 2, 3:

• 36% less effective than CCBs and 30% less effective than thiazide diuretics for cardiovascular events 2
• Did not reduce mortality (RR 0.96) or coronary heart disease (RR 0.90) 3

ACE inhibitors were less effective than thiazide diuretics and CCBs in lowering BP and preventing stroke 2

CCBs are as effective as diuretics for reducing all cardiovascular events except heart failure 2

Treatment Escalation Algorithm

Step 1: Initial Dual Therapy

Start with low-dose combination of two agents from the four major classes 1:

• Preferred combinations: RAS blocker (ACE inhibitor or ARB) + CCB, or RAS blocker + thiazide diuretic, or CCB + thiazide diuretic

Step 2: Triple Therapy

If BP remains uncontrolled, escalate to maximally tolerated triple-combination therapy 1:

• RAS blocker + CCB + thiazide diuretic

Step 3: Assess Adherence and Consider Resistant Hypertension

Before adding fourth agent 1:

• Verify medication adherence
• Confirm diagnosis with home BP monitoring (exclude white coat hypertension)
• Refer to expert center for appropriate work-up

Step 4: Fourth-Line Agent

Spironolactone (mineralocorticoid receptor antagonist) is the preferred fourth-line agent 1, 4

If spironolactone is not tolerated, consider 1:

• Eplerenone (50-200 mg, may require twice-daily dosing due to shorter duration of action)
• Other MRAs
• Vasodilating beta-blockers (labetalol, carvedilol, or nebivolol) if not already indicated—though less potent than spironolactone for resistant hypertension

Step 5: Fifth-Line and Beyond

Only after exhausting above options, consider 1:

• Hydralazine
• Other potassium-sparing diuretics (amiloride, triamterene)
• Centrally acting agents
• Alpha-blockers
• Minoxidil (only if all other agents prove ineffective due to multiple side effects)

Special Population Considerations

Black Patients

Initial therapy should include a thiazide diuretic or CCB 2:

• ACE inhibitors are notably less effective than CCBs in preventing heart failure and stroke in Black patients 2
• Thiazide diuretics (especially chlorthalidone) or CCBs are the best initial choice for single-drug therapy 2

Patients with Diabetes

Treat similarly to those without diabetes unless proteinuria is present 5:

• With proteinuria: Include an ACE inhibitor or ARB plus a thiazide diuretic or CCB 5

Patients with Chronic Kidney Disease and Proteinuria

Include an ACE inhibitor or ARB plus a thiazide diuretic or CCB 5

Patients with Heart Failure with Reduced Ejection Fraction

Initial treatment should include 5:

• Beta-blocker + ACE inhibitor or ARB (or angiotensin receptor-neprilysin inhibitor)
• Add-on therapy: Mineralocorticoid receptor antagonist + diuretic based on volume status

Blood Pressure Targets

Adults <65 years: <130/80 mmHg 1, 6

Adults ≥65 years: SBP <130 mmHg 1, 6

General target: <140/90 mmHg is the minimum acceptable threshold 6

Common Pitfalls to Avoid

Persistent use of monotherapy: More than 70% of adults with hypertension require at least two agents 5, 7. Shifting from single-drug to combination therapy significantly increases BP control rates 7

Inadequate dosing: Ensure medications are titrated to maximum or optimal dosages before adding additional agents 4

Combining two RAS blockers: Never use ACE inhibitor + ARB together 1

Using beta-blockers as first-line: Reserve for compelling indications (heart failure, post-MI, angina) 1, 2

Withdrawal rates: Be aware that thiazides and beta-blockers have higher withdrawal rates due to adverse effects (RR 2.38-4.59) compared to other first-line agents 3